Enliven Therapeutics Q3 2024 Earnings Report

Reported third quarter financial results and provided a business update, highlighting pipeline progress.

Key Takeaways

Enliven Therapeutics reported its third quarter financial results, highlighting positive data from the Phase 1 clinical trial of ELVN-001 and continued progress with ELVN-002. The company's cash position remains strong with $291.8 million, expected to provide runway into late 2026.

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks.

ELVN-001 remains well-tolerated with no dose reductions.

Continued to progress ELVN-002 with a focus on recently initiated combination clinical trials evaluating patients with HER2+ MBC and CRC.

Strong balance sheet with $292 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026.

Previous year: -$0.51

-5.9%

R&D Expenses